Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,issuanceOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,marketState,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,fax,industry
t0,IMTX,92767000.0,62908600,,,-21598000,,-21598000,8431000,-15646000,-23838000,-23838000,-239000,-105000,,,,0,7403000,31241000,23049000,2240000,,-21598000,-21598000,920000.0,581643000.0,144085000.0,93687000.0,53643000.0,237772000.0,629000.0,849000.0,-483851000.0,71707000.0,-4734000.0,589000.0,195333000.0,68003000.0,-4734000.0,14267000.0,221996000.0,21322000.0,2174000.0,10304000.0,3126000.0,-6645000.0,2559000.0,-482000.0,-482000.0,1207000.0,-12197000.0,2383000.0,-16657000.0,1094000.0,676000.0,8609000.0,-565000.0,,,153993000.0,en-US,US,EQUITY,True,Delayed Quote,13.67,1630526402,0.39000034,13.21,13.76,12.99,206512,1.8526812,0.15677677,859960576,15,America/New_York,EDT,-14400000,False,False,USD,2,Immatics N.V.,NCM,-1.36,-10.051471,12.106,1.5640001,0.12919214,11.817319,0,finmb_8986547,NasdaqCM,Immatics N.V.,EUR,100060,146257,5.005,0.5776111,8.665 - 18.42,-4.75,-0.25787187,8.665,18.42,1617107400,1617107400,1617107400,PRE,2.9367497,12.99 - 13.76,13.28,0.0,0.0,9,13,us_market,,,,18.42,8.66,12.11,11.82,100.06k,146.26k,62.91M,,28.6M,40.63%,41.31%,1.89M,13.35,4.14%,3.01%,1.86M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-260.22%,-28.60%,"-1,111.57%",31.62M,0.57,5.20%,-35.83M,-80.07M,-242.35M,,,216.66M,3.44,6.35M,6.78,3.27,,-90.82M,122.54M,Value,72076,Healthcare,285,"Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in TÃ¼bingen, Germany.",TÃ¼bingen,49 7071 5397 0,Germany,http://www.immatics.com,86400,Paul-Ehrlich-Strasse 15,49 7071 5397 900,Biotechnology
t-1,IMTX,103342000.0,62908600,,,-22588000,,-22588000,8698000,-11403000,-20030000,-20030000,-71000,-323000,,,,0,9446000,29476000,20849000,-2558000,,-22588000,-22588000,914000.0,573339000.0,150390000.0,104256000.0,46812000.0,254646000.0,629000.0,1701000.0,-462253000.0,85475000.0,-7459000.0,724000.0,207530000.0,60609000.0,-7459000.0,14017000.0,238991000.0,24448000.0,2923000.0,9554000.0,1176000.0,-7361000.0,-398000.0,-463000.0,147000.0,611000.0,-26146000.0,-150000.0,-25745000.0,887000.0,-622000.0,3257000.0,-1556000.0,8549000.0,-7939000.0,178382000.0,en-US,US,EQUITY,True,Delayed Quote,13.67,1630526402,0.39000034,13.21,13.76,12.99,206512,1.8526812,0.15677677,859960576,15,America/New_York,EDT,-14400000,False,False,USD,2,Immatics N.V.,NCM,-1.36,-10.051471,12.106,1.5640001,0.12919214,11.817319,0,finmb_8986547,NasdaqCM,Immatics N.V.,EUR,100060,146257,5.005,0.5776111,8.665 - 18.42,-4.75,-0.25787187,8.665,18.42,1617107400,1617107400,1617107400,PRE,2.9367497,12.99 - 13.76,13.28,0.0,0.0,9,13,us_market,,,,18.42,8.66,12.11,11.82,100.06k,146.26k,62.91M,,28.6M,40.63%,41.31%,1.89M,13.35,4.14%,3.01%,1.86M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-260.22%,-28.60%,"-1,111.57%",31.62M,0.57,5.20%,-35.83M,-80.07M,-242.35M,,,216.66M,3.44,6.35M,6.78,3.27,,-90.82M,122.54M,Value,72076,Healthcare,285,"Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in TÃ¼bingen, Germany.",TÃ¼bingen,49 7071 5397 0,Germany,http://www.immatics.com,86400,Paul-Ehrlich-Strasse 15,49 7071 5397 900,Biotechnology
t-2,IMTX,120690000.0,62908600,,,-177113000,,-177113000,9215000,-9614000,-18797000,-18797000,-32000,-78000,,,,0,7871000,26668000,17485000,-158316000,,-177113000,-177113000,969000.0,564852000.0,161376000.0,121659000.0,61050000.0,283035000.0,629000.0,1752000.0,-439665000.0,80295000.0,-4157000.0,632000.0,233676000.0,76190000.0,-4157000.0,14567000.0,266867000.0,25624000.0,2373000.0,9743000.0,-9601000.0,-6306000.0,-11001000.0,-465000.0,208904000.0,-17128000.0,147620000.0,-2134000.0,-48149000.0,1178000.0,-198000.0,-1360000.0,-1350000.0,209369000.0,-7939000.0,190677000.0,en-US,US,EQUITY,True,Delayed Quote,13.67,1630526402,0.39000034,13.21,13.76,12.99,206512,1.8526812,0.15677677,859960576,15,America/New_York,EDT,-14400000,False,False,USD,2,Immatics N.V.,NCM,-1.36,-10.051471,12.106,1.5640001,0.12919214,11.817319,0,finmb_8986547,NasdaqCM,Immatics N.V.,EUR,100060,146257,5.005,0.5776111,8.665 - 18.42,-4.75,-0.25787187,8.665,18.42,1617107400,1617107400,1617107400,PRE,2.9367497,12.99 - 13.76,13.28,0.0,0.0,9,13,us_market,,,,18.42,8.66,12.11,11.82,100.06k,146.26k,62.91M,,28.6M,40.63%,41.31%,1.89M,13.35,4.14%,3.01%,1.86M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-260.22%,-28.60%,"-1,111.57%",31.62M,0.57,5.20%,-35.83M,-80.07M,-242.35M,,,216.66M,3.44,6.35M,6.78,3.27,,-90.82M,122.54M,Value,72076,Healthcare,285,"Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in TÃ¼bingen, Germany.",TÃ¼bingen,49 7071 5397 0,Germany,http://www.immatics.com,86400,Paul-Ehrlich-Strasse 15,49 7071 5397 900,Biotechnology
t-3,IMTX,-69487000.0,62908600,,,-21326000,508000.0,-21043000,10076000,-5109000,-15099000,-15099000,-86000,-464000,,,,0,6896000,21995000,12005000,-6227000,,-21326000,-21043000,988000.0,193551000.0,175924000.0,-68499000.0,65745000.0,107933000.0,1164000.0,2351000.0,-262543000.0,82534000.0,-671000.0,696000.0,86056000.0,87851000.0,-671000.0,14162000.0,92087000.0,,2286000.0,8082000.0,-9601000.0,-4945000.0,-2163000.0,-557000.0,-557000.0,32126000.0,13854000.0,4000.0,16570000.0,1240000.0,-99000.0,9291000.0,-2132000.0,209369000.0,-7939000.0,4236000.0,en-US,US,EQUITY,True,Delayed Quote,13.67,1630526402,0.39000034,13.21,13.76,12.99,206512,1.8526812,0.15677677,859960576,15,America/New_York,EDT,-14400000,False,False,USD,2,Immatics N.V.,NCM,-1.36,-10.051471,12.106,1.5640001,0.12919214,11.817319,0,finmb_8986547,NasdaqCM,Immatics N.V.,EUR,100060,146257,5.005,0.5776111,8.665 - 18.42,-4.75,-0.25787187,8.665,18.42,1617107400,1617107400,1617107400,PRE,2.9367497,12.99 - 13.76,13.28,0.0,0.0,9,13,us_market,,,,18.42,8.66,12.11,11.82,100.06k,146.26k,62.91M,,28.6M,40.63%,41.31%,1.89M,13.35,4.14%,3.01%,1.86M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-260.22%,-28.60%,"-1,111.57%",31.62M,0.57,5.20%,-35.83M,-80.07M,-242.35M,,,216.66M,3.44,6.35M,6.78,3.27,,-90.82M,122.54M,Value,72076,Healthcare,285,"Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in TÃ¼bingen, Germany.",TÃ¼bingen,49 7071 5397 0,Germany,http://www.immatics.com,86400,Paul-Ehrlich-Strasse 15,49 7071 5397 900,Biotechnology
